Quantcast

Latest Biogen Idec Stories

2014-04-09 08:28:17

TEL AVIV, Israel, April 9, 2014 /PRNewswire/ -- Medison Pharma has concluded an agreement with the medical device company Brainsway for exclusive marketing and distribution of the Deep TMS (Transcranial Magnetic Stimulation) system in Israel. Medison Pharma will be Brainsway's exclusive agent for a period of 10 years with a 5 year extension option for the system's treatment of the following indications approved by the Israeli Ministry of Health: Major depression, Bipolar...

2014-04-09 08:26:02

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 9, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Actavis Plc (NYSE: ACT), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at:...

2014-04-08 23:21:41

Comprehensive cloud-based Clinical Trial Optimization System transforms clinical operations quality and efficiency from startup through closeout with a single unified platform. Newton, MA (PRWEB) April 08, 2014 TrialNetworks and its Clinical Trial Optimization System won the Disruptive Innovator and Technology of the Year award from Partnerships in Clinical Trials 2014. The award was announced on the final day of the premier industry conference held in Las Vegas, NV. The award honors an...

2014-04-01 08:29:43

Raleigh Convention Center on April 8th RALEIGH, N.C., April 1, 2014 /PRNewswire/ -- An expected 1000 life science professionals from Pfizer, Biogen Idec, Novartis, GlaxoSmithKline, Novo Nordisk, Grifols, and many others will gather at the ISPE-CaSA Life Sciences Technology Conference, Tuesday, April 8, 2014, 10:00 am-7:00 pm (http://ispe-casa.org/2014/) on the top floor of the Raleigh Convention Center, 500 S. Salisbury St., Raleigh, NC, to learn the latest manufacturing techniques through...

2014-03-31 20:22:33

DUBLIN, April 1, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5q5tcr/global_orphan) has announced the addition of the "Concise Analysis of the International Orphan Drug Market Outlook 2018" [http://www.researchandmarkets.com/research/5q5tcr/global_orphan ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The global pharmaceutical industry has been experiencing a slow growth in recent...

2014-03-27 12:30:38

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/rwdz5w/therapy_class ) has announced the addition of the "Therapy Class Overview: Rituximab biosimilar" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade,...

2014-03-27 12:30:26

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/fzv3mt/global ) has announced the addition of the "Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Positive sentiments for the biotech sector have prevailed in the last two to three years, and the authors expect this trend to continue for the next year too. The optimism is based on...

2014-03-24 12:24:47

Surveyed U.S. Payers Also Seek Improvements from New Agents in Effect on Disability, According to Findings from Decision Resources Group BURLINGTON, Mass., March 24, 2014 /PRNewswire/ -- Decision Resources Group finds that new disease-modifying therapies (DMTs) with improved efficacy in slowing disability progression present the greatest opportunity for drug developers in the treatment of relapsing-remitting multiple sclerosis (RR-MS). This finding is based on the relatively high level of...

2014-03-24 08:28:01

The Approval of ALPROLIX is First Significant Advance in Hemophilia B Treatment in More Than 17 Years CAMBRIDGE, MA, March 24, 2014 /CNW/ - Biogen Idec (NASDAQ: BIIB) has announced that Health Canada approved ALPROLIX((TM) )[Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. ALPROLIX is the first approved long-acting hemophilia B therapy and...

2014-03-22 12:21:28

DALLAS, March 22, 2014 /PRNewswire/ -- ReportsnReports.com offers "Global Orphan Drug Market Outlook 2018", "Global Orphan Drugs Market 2014-2018" and "Global Orphan Drug Pipeline Analysis" research reports in its store. The returns on investment from orphan drugs are expected to help the pharma companies to overcome the impact of revenue loss due to expiry of patents of blockbuster drugs. The major drivers for companies to increasingly invest in orphan drugs include...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related